ESC Premium Access

Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

Congress Presentation

About the speaker

Doctor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)
45 presentations
1 follower

8 more presentations in this session

Hemodynamic evaluation of patients with advanced heart failure receiving ambulatory intermittent cycles of levosimendan as bridge to transplant

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)


Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support

Speaker: Doctor T. Ichiki (Rochester, US)


Identification of patients eligible to start sacubitril valsartan in a stable heart failure population

Speaker: Doctor S. Aktaa (Leeds, GB)


What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

Speaker: Doctor P. Pellicori (Glasgow, GB)


Oral donepezil markedly suppresses the progression of cardiovascular remodeling and improves the prognosis in spontaneously hypertensive rats with myocardial infarction

Speaker: Doctor M. Li (Osaka, JP)


Access the full session

Poster Session 7 - Chronic heart failure – Treatment

Speakers: Doctor M. Senni, Doctor I. Hernandez Gonzalez, Doctor T. Ichiki, Doctor S. Aktaa, Doctor P. Pellicori...

About the event


ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb